Drugs and patents in ATC class B03AB - Iron trivalent, oral preparations

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ACCRUFER	ferric maltol
>Tradename	>Generic Name

Last updated: June 24, 2026

ATC B03AB (iron trivalent, oral preparations) covers a broad, fragmented segment with limited blockbuster-like patent estates per molecule and strong reliance on reformulation and salt/hydrate form IP. Commercial entry risk is driven more by formulation and manufacturing-process defensibility than by single, long-running platform patents. The patent landscape is dominated by (1) specific oral iron salts and their crystallization forms (polymorphs, hydrates, complexes), (2) stability and bioavailability improvements, and (3) dosing regimen and method-of-treatment claims in defined populations. In practice, many markets are already populated by generics and authorized comparators, so incremental IP plays a larger role than primary compound patents.

What products fall under ATC B03AB (iron trivalent) and how do they differentiate commercially?

ATC B03AB is “iron trivalent, oral preparations.” It typically includes oral iron(III) salts and their formulation variants used for iron deficiency anemia and related indications. Differentiation is usually based on:

Dose form: tablets, capsules, drops/syrups, chewables.
Chemical form: iron(III) salts (and iron(III)-containing complexes) and their hydrates/polymorphs.
Release and tolerability: slower release, lower gastrointestinal irritation, improved gastrointestinal tolerability versus iron(II) salts.
Bioavailability: claims tied to absorption or reduced unabsorbed iron.
Patient targeting: pediatrics, pregnancy-adjacent populations, and tolerance-driven switches.

Which iron(III) oral active forms are most common in this category?

Markets commonly use iron(III) formulations such as iron(III) polymaltose complex and other iron(III) complexes/salts in oral dosage forms. Across jurisdictions, the competitive set often includes both branded products and a large number of “generic-equivalent” versions.

How do payers and procurement behave in iron(III) oral preparations?

Commercial dynamics usually follow:

Tender pressure: oral iron is widely procured at scale via formularies and tenders, compressing unit prices quickly once generics are available.
Switching friction: tolerability and dosing frequency can slow conversion from branded to generic in some therapeutic settings.
Clinical comfort with established dosing: prescribers may keep patients on a familiar product if GI adverse events are controlled.
Hospital-to-community flows: if iron deficiency is first treated in outpatient primary care, adoption depends on guideline alignment and reimbursement.

Which patents protect ATC B03AB iron(III) oral preparations in major markets?

In iron(III) oral preparations, primary IP is often not one monolithic compound patent. Instead, protection clusters around formulation-specific attributes and manufacturing control. Typical patent categories include:

Composition of matter: specific iron(III) compounds, complexes, hydrates, or salts with defined stoichiometry or coordination environments.
Solid-state form IP: polymorphs, solvates, hydrates, amorphous forms, and crystal habit control.
Stability and compatibility: formulation excipient systems that maintain iron(III) state and reduce degradation.
Bioavailability and tolerability: process or formulation features tied to absorption or GI tolerability.
Manufacturing methods: wet chemistry routes, crystallization and drying parameters, and reproducible solid-state outcomes.
Method-of-use: iron deficiency anemia treatment protocols in specific groups.

What patent claim types show up most often?

Solid-state dependent claims: claims tied to lattice/crystal characteristics, DSC/XRD peaks, or controlled hydrate content.
Process claims: crystallization conditions, control of pH during formation, drying temperatures, and milling targets that preserve iron(III) coordination.
Formulation claims: specific excipient ratios, coating systems, and release modifiers.

How do jurisdictions affect the practical enforceability?

Europe (EP): solid-state and formulation patents can be strong if supported by enabling data and validated analytical characterization. Enforcement depends heavily on national courts and claim construction.
US (Orange Book and Hatch-Waxman): for iron(III) oral drugs, exclusivity and listed patents drive generic timing when an ANDA exists; if the product is not subject to Hatch-Waxman listings or if the listed patents do not map cleanly, generic entry accelerates.
UK/EU national phases: enforcement and injunction outcomes can differ materially across countries.

When do patents and exclusivities for iron(III) oral preparations lose exclusivity?

Featured snippet answer: Exclusivity loss in ATC B03AB is usually driven by the expiration of formulation-specific patents and any associated regulatory exclusivities tied to specific reference products, not by a single category-wide expiry date.

A precise “category calendar” is not feasible because B03AB spans multiple active ingredients and reference products with independent filing dates, prosecution outcomes, and patent listing behaviors. In practice, the market’s exclusivity horizon is managed product-by-product:

If a branded reference product has active Orange Book-listed patents, generic launch timing is constrained by those listed patents.
If the market is already generic-heavy, the remaining barriers are often “late” patent families (reformulations, new dosage forms, new solid-state forms) whose expirations are shorter and whose claim scope is narrower.

What timing signals matter for launch risk?

Expiration of last composition-of-matter or solid-state patents tied to the specific marketed formulation.
Status of any pediatric exclusivity (if attached to the reference NDA and relevant).
Whether ANDA or 505(b)(2) pathways were used historically and whether listed patents were successfully cleared via settlement or litigation.

What generic entry risks exist for ATC B03AB iron(III) oral preparations?

Generic risks usually cluster into three buckets:

Claim-mapping risk
- If a generic cannot design around the listed solid-state or hydrate form claims, it may trigger an infringement dispute.
Regulatory risk
- If the reference drug is protected by listed patents in the US, a Paragraph IV challenge can cause launch delays via litigation or settlement.
- For non-US markets, local regulatory timelines and patent linkages determine practical entry date.
Commercial risk
- Even if a product is technically permissible, payer and prescriber acceptance can lag, especially where tolerability claims are a key differentiator.

What are the most common “design-around” strategies?

Switching to a different iron(III) complex chemistry that avoids the specific solid-state form claimed.
Using a different hydrate content or polymorph with separate solid-state signatures.
Reformulating with distinct excipient/release systems while meeting equivalence specifications.

How strong is the patent estate for iron(III) oral preparations: formulation vs compound protection?

Featured snippet answer: For ATC B03AB, patent strength is usually highest in formulation and solid-state families, and lowest in broad “iron(III) salt” concept claims.

Typical strength profile in practice

Strong: patents that clearly define a unique solid-state form and provide analytical support that is difficult to reproduce inadvertently.
Moderate: process patents where infringement depends on manufacturing evidence and access to batch records.
Weak: broad claims that attempt to cover wide sets of iron(III) salts without clear structural boundaries.

What makes formulation patents enforceable?

Tight characterization (XRD patterns, IR/Raman bands, DSC profiles).
Evidence of functional properties (stability in GI conditions, reduced degradation, consistent bioavailability).
Clear link between form and improved attributes.

What patent litigation affects ATC B03AB iron(III) oral preparations?

Featured snippet answer: Litigation, when present, concentrates on reformulated products and solid-state equivalence in the US (ANDA/Paragraph IV) and in Europe via national infringement actions on formulation claims.

Common litigation themes for iron(III) oral drugs:

Infringement disputes over whether the accused generic uses the same hydrate/polymorph.
Infringement disputes over manufacturing conditions that drive the solid-state outcome.
Validity challenges attacking novelty and inventive step for known iron(III) forms.
Settlement-driven generic entry timing, if a Paragraph IV challenge triggers 30-month stay or earlier settlement.

How does ATC B03AB compare with ATC B03AA (iron(II) oral preparations) on patent and market dynamics?

Featured snippet answer: Compared with iron(II) oral preparations, iron(III) oral products often build defensibility around formulation tolerability and solid-state stability rather than around broad compound IP.

Key differences

Market acceptance: iron(II) salts are historically entrenched and often priced lower; iron(III) is frequently positioned on tolerability.
Patent defensibility: iron(III) products often have more reformulation and complexation IP that maps to specific solid-state behaviors.
Generic conversion: once bioequivalence and equivalence criteria are met, competitive substitution tends to be fast, pressuring brand margins.

What is the Orange Book status of iron(III) oral preparations?

Featured snippet answer: Orange Book status is product-specific, tied to each listed NDA reference drug. Patent listings and their expiration dates determine US generic launch timelines.

B03AB cannot be summarized without specifying the reference product, because:

Different branded iron(III) oral drugs have different listed patents.
Some products may have limited or no relevant Orange Book coverage by the time the market is contested.
Patent litigation and settlements reshape practical entry dates independently of theoretical expiration.

How do settlement agreements and Paragraph IV challenges shape revenue exposure in this segment?

Featured snippet answer: In ATC B03AB, revenue exposure typically hinges on whether the branded product faces Paragraph IV challenges on formulation/solid-state patents, and on whether settlements allow early generic entry.

Practical revenue implications

High unit volumes, low unit margins: delays of even 6 to 18 months matter because the segment is tender-driven.
Switch-timing effects: once a generic launches, switching can be rapid, especially where prescribers prioritize tolerability improvements that generics can match.
Litigation cost vs value: companies often litigate only the most valuable formulations and presentations (strengths, dosage forms, and pediatric lines).

What formulations are protected by patent estates in iron(III) oral preparations?

In this category, protection is usually strongest for:

Specific dosage forms (extended release, coated tablets, granules).
Specific strengths where manufacturing differences change the solid-state profile.
Specific solid-state forms (hydrated forms, specific polymorphs).
Specific complexation structures (stoichiometric complexes, defined coordination environments).

Formulation-by-formulation exposure logic

If a patent family covers only one strength and dosage form, manufacturers can launch other strengths sooner through product line segmentation.
If a family covers a broad process outcome (e.g., “the hydrate obtained by drying under X”), design-arounds must replicate or avoid the outcome, which can be harder for generic formulators without access to manufacturing controls.

Which companies are most exposed to competitive pressure in ATC B03AB?

Featured snippet answer: Exposure is concentrated among holders of branded iron(III) oral references with remaining formulation patents, especially those competing in tender-heavy markets.

Across ATC B03AB, competitive pressure tends to come from:

Multi-source generic manufacturers with established oral solid-state manufacturing platforms.
Authorized generic arrangements where brand holders seek to manage price erosion through licensing.

Key Takeaways

ATC B03AB (iron trivalent, oral preparations) is a formulation and solid-state IP battleground more than a single-compound exclusivity story.
Patent strength typically concentrates in specific hydrate/polymorph and manufacturing-defined complex/solid-state families.
Generic entry risk is governed by whether active, enforceable formulation patents are mapped to the marketed reference product, especially in the US via Orange Book-listed patents.
Revenue exposure is driven by litigation and settlements tied to formulation/solid-state claims and by rapid tender-based switching once generic supply is established.
The segment’s commercial dynamics favor incumbents with defensible, narrow formulation IP and favor generics that can credibly design around by changing solid-state form and process outcomes.

FAQs

1) What drives patentability for iron(III) oral supplements: active ingredients or solid-state forms?
Solid-state forms (hydrates/polymorphs) and formulation attributes typically drive patentability and enforceability more than broad “iron(III) salt” concepts.

2) Are Paragraph IV challenges common for iron(III) oral preparations?
They occur when Orange Book-listed formulation patents remain active for a reference product and claim scope maps tightly to the marketed formulation.

3) Can generics avoid infringement without changing the iron(III) chemistry?
Often the design-around is solid-state and formulation-based, but success depends on whether the remaining claims are broad versus tightly limited to specific hydrate/polymorph signatures.

4) How do dosing strength and dosage form affect exclusivity and litigation outcomes?
Patent estates frequently protect specific strengths and presentations, allowing earlier entry for non-covered strengths or dosage forms.

5) What is the biggest commercial risk for brand holders in ATC B03AB?
Fast tender-driven price erosion after generic launch, even if clinical differentiation on tolerability is modest.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
FDA. Hatch-Waxman Drug Products: “Orange Book” and related regulatory guidance. (Accessed via FDA guidance and drug approval resources).

Drugs in ATC Class B03AB

Drugs in ATC Class: B03AB - Iron trivalent, oral preparations

Market dynamics and patent landscape for ATC Class B03AB (trivalent iron, oral preparations)